Insider trades
OrbiMed Advisors Israel II, Director of ADARx Pharmaceuticals ADRX, has filed 14 purchases and 40 sales on the open market. Over the past 12 months that comes to a net purchase of $20.5M. The latest trade was on 09/28.
OrbiMed Advisors Israel II
Director
- Company
- ADARx Pharmaceuticals ADRX
- First filing
- 23/06/29
- Trades
- 76 trades
- Buys / sales
- 14 / 40
- 12-month net buying
- $20.5M
- Last trade
- 09/28
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
ADRX | Open-market buy | 09/28 | 09/30 | 950,000 sh3 trades | $17.00avg. | $16,150,000 | No record |
ACET | Open-market sale | 04/07–04/08 | 04/09 | 104,658 sh4 trades | $6.45avg. | $674,847.06 | −100.0% |
ACET | Open-market buy | 25/10/08 | 25/10/10 | 5,000,000 sh2 trades | $1.00avg. | $5,000,000 | No record |
UPB | Open-market buy | 24/10/15 | 24/10/17 | 825,000 sh2 trades | $17.00avg. | $14,025,000 | +22.1% |
ACET | Open-market buy | 24/01/25 | 24/01/26 | 3,125,000 sh3 trades | $2.40avg. | $7,500,000 | No record |
DMRA | Open-market sale | 23/08/15 | 23/08/17 | 822,680 sh3 trades | $0.75avg. | $617,010 | −35.3% |
DMRA | Open-market sale | 23/07/31 | 23/08/02 | 209,400 sh3 trades | $3.00avg. | $628,200 | −9.0% |
DMRA | Open-market sale | 23/07/25 | 23/07/27 | 39,200 sh3 trades | $2.92avg. | $114,464 | −1.7% |
DMRA | Open-market sale | 23/07/13 | 23/07/17 | 194,700 sh3 trades | $2.40avg. | $467,280 | −7.8% |
ACET | Open-market buy | 23/06/27 | 23/06/29 | 875,000 sh4 trades | $2.09avg. | $1,828,750 | No record |
DMRA | Open-market sale | 23/04/13–23/04/17 | 23/04/17 | 68,481 sh9 trades | $1.87avg. | $128,256.61 | −2.8% |
DMRA | Open-market sale | 23/04/10–23/04/12 | 23/04/12 | 67,537 sh9 trades | $1.80avg. | $121,356.87 | −2.7% |
DMRA | Open-market sale | 23/04/05–23/04/06 | 23/04/07 | 102,630 sh6 trades | $2.16avg. | $221,993.7 | −3.9% |
